LXEO Lexeo Therapeutics Forecast, Technical & Fundamental Analysis
Lexeo Therapeutics Inc is a clinical-stage genetic medicine company engaged in the development of gene therapy candidates targeting the underlying genetic causes of cardiovascular diseases... Show more
LXEO is expected to report earnings to rise 204.00% to -75 cents per share on August 19
Q2'26
Est.
$-0.76
Q1'26
Beat
by $0.49
Q4'25
Beat
by $0.59
Q3'25
Beat
by $0.51
Q2'25
Beat
by $0.31
The last earnings report on May 11 showed earnings per share of -25 cents, beating the estimate of -74 cents. With 393.87K shares outstanding, the current market capitalization sits at 395.75M.
A.I.dvisor indicates that over the last year, LXEO has been loosely correlated with SLDB. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if LXEO jumps, then SLDB could also see price increases.
LXEO's RSI Oscillator recovers from oversold territory
The RSI Oscillator for LXEO moved out of oversold territory on June 11, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 12 similar instances when the indicator left oversold territory. In of the 12 cases the stock moved higher. This puts the odds of a move higher at .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on June 16, 2026. You may want to consider a long position or call options on LXEO as a result. In of 42 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for LXEO just turned positive on June 15, 2026. Looking at past instances where LXEO's MACD turned positive, the stock continued to rise in of 28 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where LXEO advanced for three days, in of 161 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LXEO declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for LXEO entered a downward trend on June 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.709) is normal, around the industry mean (20.966). P/E Ratio (0.000) is within average values for comparable stocks, (36.007). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.690). LXEO has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.038). P/S Ratio (0.000) is also within normal values, averaging (367.026).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. LXEO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LXEO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
